Question Title

1. Name

Question Title

2. NABP ID

Question Title

3. Date of Birth (in MMDD format)

Question Title

4. Email

Question Title

5. Practice Setting

Question Title

6. Please rate if the Learning Objectives were met:

  Strongly Disagree Strongly Agree
Describe current trends in antimicrobial resistance and mechanisms of resistance utilized by Gram-negative pathogens that commonly cause hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
Differentiate among newer antimicrobial agents that target multidrug-resistant Gram-negative bacteria
Evaluate evidence-based strategies to optimally utilize the current selection of antimicrobial agents in a pathogen-specific manner when managing HABP/VABP

Question Title

7. Please rate faculty, James S. Lewis II, PharmD, FIDSA

  Poor Excellent
Teaching ability
Knowledge and expertise in the subject

Question Title

8. Overall Activity Satisfaction

  Strongly Disagree Strongly Agree
The content was relevant to my practice and educational needs.
Activity slides were clear and useful.
Patient Case was valuable and increased knowledge application.
I intend to make changes based on participating in this activity.
The activity was fair, balanced, and without commercial bias.

Question Title

9. Your Commitment to Change: Please list changes you plan to implement based on participating in this activity (Select all that apply)

Question Title

10. What are the barriers you anticipate that may impact implementation of these changes? (Select all that apply)

Question Title

11. The average number of patients you see each month with suspected HABP/VABP symptoms is:

Question Title

12. Which of the following pathogens is not included as an urgent or serious threat by the Centers for Disease Control and Prevention?

Question Title

13. Risk factors for a multidrug-resistant ventilator-associated bacterial pneumonia (VABP) include all of the following except:

Question Title

14. Which of the following agents would be preferred for the treatment of hospital-acquired bacterial pneumonia (HABP) caused by MDR P. aeruginosa?

Question Title

15. Which of the following newer antimicrobials exhibits in vitro activity against metallo-beta-lactamases?

Question Title

16. Additional Comments?

Thank you for participating and completing this form. Please visit www.vemcomeded.com for additional educational opportunities. 

T